Sarcopenia in cancer: Risking more than muscle loss
| Autor: | Michael Corden, Peter Hoskin, Milan Anjanappa, Darren L. Roberts, Andrew Green, Alan McWilliam, Ananya Choudhury |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
lcsh:Medical physics. Medical radiology. Nuclear medicine
Sarcopenia medicine.medical_specialty lcsh:R895-920 Degeneration (medical) lcsh:RC254-282 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine medicine Chemotherapy Radiology Nuclear Medicine and imaging Intensive care medicine Care Planning Cancer Radiotherapy Muscle loss Oncology (nursing) business.industry Health Policy Skeletal muscle Biomarker lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Prognosis musculoskeletal system medicine.disease body regions medicine.anatomical_structure Ageing 030220 oncology & carcinogenesis Etiology Biomarker (medicine) business human activities Research Article |
| Zdroj: | Technical Innovations & Patient Support in Radiation Oncology Technical Innovations & Patient Support in Radiation Oncology, Vol 16, Iss, Pp 50-57 (2020) |
| ISSN: | 2405-6324 |
| Popis: | Sarcopenia is characterised by progressive and extensive skeletal muscle degeneration and is associated with functional decline. Sarcopenia has primary and secondary aetiology, arising as a result of the ageing process or through chronic cytokine-mediated inflammation (associated with health conditions including cancer), respectively. Diagnosis of sarcopenia is dependent upon detection of reduced skeletal muscle strength, mass and performance. A combination of non-radiological and radiological methods can be used to assess each of these in turn to accurately diagnose sarcopenia. Sarcopenia is known to adversely affect outcomes of patients with various forms of cancer. Early identification of sarcopenia is imperative in improving patient care and overall prognosis. Various interventions, such as resistance exercise, nutritional support, and amino acid and vitamin supplementation have shown promise in the management of sarcopenia. However, further insight into novel interventions and indeed, assessment of the benefits of management of sarcopenia in terms of survival, are required to better support cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|